You go to your doctor for a routine checkup. They run some blood work. A few days later, you get a call about your liver.
Fatty liver disease affects about one in three adults worldwide. It is the most common chronic liver condition on the planet. And right now, doctors have no simple blood test to diagnose it.
Many people hoped that a well-known heart risk marker called lipoprotein(a) could fill that gap. A new study says that hope was wrong.
Researchers combined data from 21 studies covering more than 418,000 adults. They compared people with metabolic fatty liver disease (called MASLD) to people without it.
The result was clear. There was no meaningful difference in Lp(a) levels between the two groups.
The average difference was just 1.40 mg/dL. Statistically, that number is essentially zero. The researchers called it "not significant."
This matters because Lp(a) is a standard blood test. It is cheap, widely available, and already used to check heart attack risk. If it had worked for the liver, millions of people could have been screened with a simple blood draw.
But here is the twist. The old thinking went like this. Fatty liver disease causes inflammation. Inflammation changes how the body handles fats. So Lp(a) levels should shift too.
The new data says that logic does not hold up in real patients.
Why the liver and heart are still connected
Think of Lp(a) as a sticky particle floating in your blood. It is made of fat and protein. For years, doctors have known that high levels increase your risk of heart attacks and strokes.
Fatty liver disease also raises heart risk. So the two conditions often travel together. But this study shows they travel on separate roads.
The liver stores fat. The blood carries Lp(a). These are different systems. One does not predict the other.
This does not mean the Lp(a) test is useless for people with fatty liver.
It just means the test cannot tell you whether you have liver fat. It can still tell you about your heart risk. And people with fatty liver disease do need to watch their heart health closely.
The researchers looked at 137,494 people with fatty liver disease and 281,261 healthy controls. That is a massive sample size. When a study this large finds nothing, the finding is reliable.
The problem was that individual studies varied a lot. Some showed slightly higher Lp(a) in fatty liver patients. Others showed slightly lower. When you average them all out, the result is flat.
This variation is called heterogeneity. It means the answer is not simple. Different populations, different lab methods, and different definitions of fatty liver all played a role.
But there is a catch
The study only looked at one moment in time. It did not track patients over years. So we cannot say whether Lp(a) changes as fatty liver gets better or worse.
Also, most of the studies were observational. That means they show a snapshot, not a cause-and-effect relationship.
The researchers are honest about this. They say future studies need to follow patients over time. That is the only way to know if Lp(a) matters for long-term liver outcomes.
If you have fatty liver disease, do not ask your doctor to check your Lp(a) for that reason. It will not help diagnose or track your liver condition.
But if you have fatty liver and have never checked your Lp(a) for heart risk, that is a different conversation. Heart disease is the number one cause of death in people with fatty liver. Knowing your Lp(a) level could help your doctor manage that risk.
The bottom line is simple. One test cannot do everything. Lp(a) remains a powerful tool for heart health. It just is not a tool for liver health.
What happens next
Researchers will now look for other blood markers that might work for fatty liver. Some candidates include certain liver enzymes, inflammatory proteins, and genetic tests.
But none of these are ready for routine use. The search for a simple blood test for fatty liver disease continues.
For now, the best way to diagnose MASLD remains imaging tests like ultrasound or a liver biopsy. Neither is perfect. Ultrasound is not always accurate. Biopsy is invasive.
This is why research matters. Every negative result moves science closer to a real answer. This study closes one door. But it opens the door to finding the right marker next time.
